Investigation of the Underlying Mechanism of Sclerosteosis Expression in Muscle Tissue in Multiple Myeloma with Sarcopenia

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2023 Feb 23

PMID 36818195

Authors

Jie Ren

Jingzhou Wang

Xingchen Yao

Yue Wu

Ming Shi

Xiangjun Shi

Xinru Du

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the role of sclerosteosis (SOST) gene expression in the occurrence and development of multiple myeloma (MM) complicated with sarcopenia.

Methods: Analysis of the SOST expression in skeletal muscle tissue of patients with MM using high-throughput sequencing combined with transcriptomics; observation of morphological changes of the mouse C2C12 myoblasts co-cultured with SP2/0 myeloma cells in Transwell; observation of the SOST expression in the C2C12 myoblasts using the immunofluorescence labeling method; and assessment of the changes in exercise capacity of mice with MM using ethology; and the measurement of the SOST expression in muscles of mice using immunohistochemistry.

Results: The transcription level of the SOST gene in the muscle tissue was significantly higher in patients with MM and sarcopenia than in patients with MM without sarcopenia and elderly patients with sarcopenia; the area of C2C12 mouse myoblasts co-cultured with SP2/0 myeloma cells was 167,904 ± 8653.7 pix; this was significantly lower than the area of 402,994 ± 13,575.0 pix in the control group (CG); the fluorescence intensity of SOST in the cells of the experimental group (EG) was 159,389 ± 10,534 AU; this was significantly higher than the intensity of 26,338 ± 6059 AU in the CG; the differences in results of the coat-hanger test, the tail suspension test, the weight-bearing forced swimming test, and the grip strength test between the tumor-bearing mice in the EG and the CG were statistically significant; and the quantitative result of SOST expression in the muscle tissue of the EG mice was 11,515 ± 1573 pix; this was significantly higher than the result of 3399 ± 798.8 pix in the CG.

Conclusion: The SOST gene expression was significantly higher in muscle of mice in EG than in CG; and increased SOST gene expression might be a pathogenesis of MM complicated with sarcopenia.

Citing Articles

Myricanol prevents aging-related sarcopenia by rescuing mitochondrial dysfunction via targeting peroxiredoxin 5.

Shen S, Liao Q, Lyu P, Wang J, Lin L MedComm (2020). 2024; 5(6):e566.

PMID: 38868327 PMC: 11167181. DOI: 10.1002/mco2.566.

All- Retinoic Acid and Beta-Carotene Increase Sclerostin Production in C2C12 Myotubes.

Ewendt F, Lehmann A, Wodak M, Stangl G Biomedicines. 2023; 11(5).

PMID: 37239103 PMC: 10216713. DOI: 10.3390/biomedicines11051432.

References

Gnoni A, Brunetti O, Longo V, Calabrese A, Argentiero A, Calbi R . Immune system and bone microenvironment: rationale for targeted cancer therapies. Oncotarget. 2020; 11(4):480-487. PMC: 6996902. DOI: 10.18632/oncotarget.27439. View

Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M . Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10(5):537-43. DOI: 10.1093/hmg/10.5.537. View

Sutherland M, Geoghegan J, Yu C, Winkler D, Latham J . Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone. 2004; 35(2):448-54. DOI: 10.1016/j.bone.2004.04.019. View

Tarantino U, Baldi J, Celi M, Rao C, Liuni F, Iundusi R . Osteoporosis and sarcopenia: the connections. Aging Clin Exp Res. 2013; 25 Suppl 1:S93-5. DOI: 10.1007/s40520-013-0097-7. View

Sebastian A, Loots G . Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models. Metabolism. 2017; 80:38-47. DOI: 10.1016/j.metabol.2017.10.005. View

Rier H, Jager A, Meinardi M, van Rosmalen J, Kock M, Westerweel P . Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatment. Support Care Cancer. 2017; 26(6):1781-1789. DOI: 10.1007/s00520-017-4018-8. View

Cooper A, Slack R, Fogelman D, Holmes H, Petzel M, Parker N . Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Ann Surg Oncol. 2014; 22(7):2416-23. PMC: 11831732. DOI: 10.1245/s10434-014-4285-2. View

Jilka R, Weinstein R, Bellido T, Roberson P, Parfitt A, Manolagas S . Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999; 104(4):439-46. PMC: 408524. DOI: 10.1172/JCI6610. View

van Bezooijen R, Roelen B, Visser A, van der Wee-Pals L, de Wilt E, Karperien M . Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199(6):805-14. PMC: 2212719. DOI: 10.1084/jem.20031454. View

10.

Arron J, Choi Y . Bone versus immune system. Nature. 2000; 408(6812):535-6. DOI: 10.1038/35046196. View

11.

Harimoto N, Shirabe K, Yamashita Y, Ikegami T, Yoshizumi T, Soejima Y . Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013; 100(11):1523-30. DOI: 10.1002/bjs.9258. View

12.

Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5. View

13.

Russell R . Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006; 1068:367-401. DOI: 10.1196/annals.1346.041. View

14.

Cruz-Jentoft A, Sayer A . Sarcopenia. Lancet. 2019; 393(10191):2636-2646. DOI: 10.1016/S0140-6736(19)31138-9. View

15.

Honma M, Ikebuchi Y, Kariya Y, Hayashi M, Hayashi N, Aoki S . RANKL subcellular trafficking and regulatory mechanisms in osteocytes. J Bone Miner Res. 2013; 28(9):1936-49. DOI: 10.1002/jbmr.1941. View

16.

Li G, Zhang L, Wang D, AIQudsy L, Jiang J, Xu H . Muscle-bone crosstalk and potential therapies for sarco-osteoporosis. J Cell Biochem. 2019; 120(9):14262-14273. PMC: 7331460. DOI: 10.1002/jcb.28946. View

17.

Daly L, Ni Bhuachalla E, Power D, Cushen S, James K, Ryan A . Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle. 2018; 9(2):315-325. PMC: 5879982. DOI: 10.1002/jcsm.12267. View

18.

Adams S, Segal R, McKenzie D, Vallerand J, Morielli A, Mackey J . Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. Breast Cancer Res Treat. 2016; 158(3):497-507. DOI: 10.1007/s10549-016-3900-2. View

19.

Lintern K, Guidato S, Rowe A, Saldanha J, Itasaki N . Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J Biol Chem. 2009; 284(34):23159-68. PMC: 2755721. DOI: 10.1074/jbc.M109.025478. View

20.

Reiss J, Iglseder B, Alzner R, Mayr-Pirker B, Pirich C, Kassmann H . Sarcopenia and osteoporosis are interrelated in geriatric inpatients. Z Gerontol Geriatr. 2019; 52(7):688-693. PMC: 6817738. DOI: 10.1007/s00391-019-01553-z. View